Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic Leukemia
The objective of this study is to determine the efficacy and safety of imatinib mesylate in patients diagnosed as having Philadelphia chromosome positive acute lymphocytic leukemia (ALL).
Philadelphia Chromosome Positive Acute Lymphocytic Leukemia
DRUG: Imatinib Mesylate
3 month hematological response rate
Duration of hematological response|Survival|Cytogenetic response in every 3 months
The objective of this study is to determine the efficacy and safety of imatinib mesylate in patients diagnosed as having Philadelphia chromosome positive acute lymphocytic leukemia (ALL).